
-
Jan 23, 2024Full-Life Technologies and Eckert & Ziegler Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
Gembloux, Belgium and Berlin, Germany – Jan. 23, 2024 – Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company and Eckert & Ziegler (ISIN DE0005659700, SDAX) today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225).
Read More -
Jan 04, 2024Global radiotherapeutics company Full-Life Technologies announces USD $47.3 million Series B financing, Prosperity7 Ventures jointly leads the round
Shanghai, Gembloux, Belgium, and Heidelberg, Germany - Jan. 4, 2024 - Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities.
Read More -
Dec 08, 2023Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals
Gembloux, Belgium - Dec. 08, 2023 - Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals.
Read More -
May 04, 2023Full-Life Technologies Announces Land Purchase in Belgium to Establish GMP Manufacturing Facility for Radiopharmaceutical Drug Production
Full-Life Technologies announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP).
Read More -
Jan 17, 2023Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer
Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
Read More